Hypothesis

Senescent cells actively maintain plasma levels of Factor VIII (FVIII) and von Willebrand factor (vWF) in aging tissue through paracrine SASP signaling that reprograms endothelial transcriptional programs and suppresses clearance pathways. Consequently, senolytic removal of these cells will lower FVIII/vWF, shifting hemostasis toward a hypocoagulable state and increasing bleeding risk, counteracting their established role in thrombosis.

Mechanistic Basis

• SASP cytokine signaling: IL‑6 and TNF‑α, core SASP components, activate STAT3 and NF‑κB pathways in hepatic sinusoidal and lung endothelial cells, driving transcription of the F8 and VWF genes via hypoxia‑responsive elements (HREs) that become accessible under SASP‑induced HIF‑1α stabilization
• Extracellular vesicle cargo: Senescent cell‑derived exosomes carry miR‑21 and miR‑155 that inhibit ADAMTS13 mRNA translation, reducing vWF cleavage and prolonging plasma vWF half‑life
• Feedback loop: Elevated FVIII/vWF enhances thrombin generation, which in turn reinforces senescence through protease‑activated receptor (PAR) signaling, creating a self‑limiting circuit that prevents runaway coagulation while preserving hemostatic capacity

These mechanisms extend the "hostage negotiator" concept by specifying molecular routes through which senescent cells modulate the coagulation axis rather than merely passively accumulating.

Experimental Design

Model: Aged (24‑month) C57BL/6 mice with inducible p16^INK4a‑driven senescence (p16‑3MR) allowing timed senolytic administration (ganciclovir or navitoclax). Groups:

1. Young control (3‑month)
2. Aged vehicle
3. Aged + senolytic (short‑term, 2 weeks)
4. Aged + SASP neutralization (anti‑IL‑6/TNF‑α antibodies)
5. Aged + senolytic + recombinant FVIII/vWF rescue

Readouts (performed blind):

• Plasma FVIII activity (chromogenic assay) and vWF antigen (ELISA)
• ADAMTS13 activity (FRET‑based)
• Thromboelastography (TEG) for clot strength and lysis
• Tail‑bleeding time and FeCl3‑induced carotid thrombosis model
• Hepatic and lung endothelial HIF‑1α, STAT3, NF‑κB nuclear localization (immunofluorescence)
• Exosomal miR‑21/miR‑155 levels (qPCR)

Predicted Outcomes

• Senescent‑intact aged mice will show elevated FVIII (~+12 IU/dL) and vWF (~+10 IU/dL) versus young, correlating with increased ADAMTS13 inhibition.
• Senolytic treatment will reduce FVIII/vWF by ≥30 %, lower ADAMTS13 activity, prolong tail‑bleeding time (>2 × baseline), and decrease thrombus weight in the carotid model.
• SASP neutralization will phenocopy senolytic effects on coagulation, confirming cytokine mediation.
• Recombinant FVIII/vWF rescue will normalize bleeding times without affecting senescence markers, indicating that the hemostatic shift is downstream of SASP.

Potential Confounds and Controls

• Inflammation independent of senescence: measure IL‑1β and CRP to ensure observed changes are not driven by acute infection.
• Platelet contribution: assess platelet count and activation (P‑selectin) to separate endothelial from platelet sources of vWF.
• Off‑target senolytic toxicity: include liver/kidney function panels (ALT, AST, BUN, creatinine).

Falsification: If senolytic clearance does not alter plasma FVIII/vWF levels or bleeding/thrombosis phenotypes, the hypothesis that senescent cells actively regulate these coagulation factors would be refuted, directing focus toward alternative sources of age‑related hemostatic change.